Drug-induced erythropoiesis and outcome: should we give up the haemoglobin target approach and return to the ratio between erythropoiesis-stimulating agents and haemoglobin?
Canavese, C.; Salomone, M.; Stratta, P.
Nephrology Dialysis Transplantation Official Publication of the European Dialysis and Transplant Association - European Renal Association 27(1): 454; Author Reply 454-5
2012
ISSN/ISBN: 0931-0509 PMID: 22287705 DOI: 10.1093/ndt/gfr660
Accession: 052722892
Full Text Article emailed within 0-6 h: $19.90
Related References
Locatelli, F.; Del Vecchio, L. 2011: Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach? Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 26(7): 2069-2071Santacana-Juncosa, E.èn.; Padullés-Zamora, N.úr.; Padullés-Zamora, A.; Comas-Sugrañes, D.; Santulario-Verdú, L.; Sanmartí-Martínez, N.úr.; Martínez-Castelao, A. 2014: Is there a difficulty in maintaining haemoglobin target levels in pre-dialysis patients treated with erythropoiesis-stimulating agents? Nefrologia: Publicacion Oficial de la Sociedad Espanola Nefrologia 34(2): 263-264
Holter, P.H.; Sanengen, T.; Halvorsen, S.; Refsum, H.E. 1986: Erythropoiesis-stimulating factor(s), erythropoiesis and erythrocyte 2,3-diphosphoglycerate in young rabbits with marked post-natal fall in haemoglobin Acta Physiologica Scandinavica 126(4): 583-587
Locatelli, F.; Aljama, P.; Canaud, B.; Covic, A.; De Francisco, A.; Macdougall, I.C.; Wiecek, A.; Vanholder, R.; Abramovicz, D.; Cannata-Andia, J.; Cochat, P.; Eckardt, K.U.; Fouque, D.; Heimburger, O.; Jäger, K.J.; Jenkins, S.; Lindley, E.; London, G.; MacLeod, A.; Marti-Munros, A.; Spasovski, G.; Tattersall, J.; van Biesen, W.; Wanner, C.; Zoccali, C. 2010: Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 25(9): 2846-2850
Kawahara, K.; Minakuchi, J.; Yokota, N.; Suekane, H.; Tsuchida, K.; Kawashima, S. 2015: Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis Nephrology 20(Suppl 4): 29-32
Hayashi, T.; Nagamatsu, T.; Matsushita, A.; Mizuno, T.; Nishibe, S.; Noguchi, A.; Kato, R.; Toda, T.; Tanaka, J.; Takahashi, H.; Hayashi, H.; Yuzawa, Y.; Yamada, S. 2015: Comparison between Long- and Short-Acting Erythropoiesis-Stimulating Agents in the Period Required for Haemoglobin Stabilisation in Treatment of Anaemia in Patients with Chronic Kidney Disease Biological and Pharmaceutical Bulletin 38(5): 740-745
Locatelli, F.; Altieri, P.; Andrulli, S.; Sau, G.; Bolasco, P.; Pedrini, L.A.; Basile, C.; David, S.; Feriani, M.; Nebiolo, P.E.; Ferrara, R.; Casu, D.; Logias, F.; Tarchini, R.; Cadinu, F.; Passaghe, M.; Fundoni, G.; Villa, G.; Di Iorio, B.R.; Zoccali, C. 2012: Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 27(9): 3594-3600
Higashiura, M.; Ohya, M.; Tanaka, Y.; Yano, T.; Yamamoto, S.; Mima, T.; Negi, S.; Shigematsu, T. 2020: Correlation between haemoglobin level and type of erythropoiesis-stimulating agent at initiation of haemodialysis International Journal of Clinical Pharmacy 42(2): 635-641
Hazara, A.M.; Owen, S.J.; Bhandari, S. 2016: The Impact of Lowering Haemoglobin Targets on Patterns of Erythropoiesis-Stimulating Agent use in Patients on Haemodialysis Blood Purification 41(4): 287-292
Birnie, K.; Caskey, F.; Ben-Shlomo, Y.; Sterne, J.A.C.; Gilg, J.; Nitsch, D.; Tomson, C. 2017: Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005-13 Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 32(4): 692-698
Bernieh, B.; Abouchacra, S.; Boobes, Y.; Al Hakim, M.R.; Nagelkerke, N.; Chaaban, A.; Ahmed, M.; Hussain, Q.; Jack, H.E.; Abayechi, F.; Khan, I.; Gebran, N. 2014: Comparison between short- and long-acting erythropoiesis-stimulating agents in hemodialysis patients: target hemoglobin, variability, and outcome International Urology and Nephrology 46(2): 453-459
Pérez-Ruixo, J.José.; Cucala-Ramos, M.; García-Gonzalo, E.; Del Val Romero, B.; Valveny, N. 2013: Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis British Journal of Clinical Pharmacology 75(1): 15-25
Regidor, D.; McClellan, W.M.; Kewalramani, R.; Sharma, A.; Bradbury, B.D. 2011: Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009 Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 26(5): 1583-1591
Graf, H.; Lacombe, J.L.; Braun, J.; Da Costa, A.A. Gomes 2000: Novel erythropoiesis stimulating protein for maintaining haemoglobin at a reduced dose frequency compared to recombinant human erythropoietin in ESRD patients Nephrology Dialysis Transplantation 15(9): A159
Honda, H.; Kobayashi, Y.; Onuma, S.; Shibagaki, K.; Yuza, T.; Hirao, K.; Yamamoto, T.; Tomosugi, N.; Shibata, T. 2016: Associations among Erythroferrone and Biomarkers of Erythropoiesis and Iron Metabolism, and Treatment with Long-Term Erythropoiesis-Stimulating Agents in Patients on Hemodialysis Plos one 11(3): E0151601
Burton, T.; Larholt, K.; Pashos, C.L.; Peake, C.; Bookhart, B.K.; Corral, M.; Piech, C.T.; McKenzie, R.S. 2016: Transfusion outcomes among oncology patients initiated with erythropoiesis-stimulating agents (ESAs) at baseline (BL) hemoglobin (Hb) of <10 versus 10-11g/dL: Observational data from the dosing and outcomes study of erythropoiesis-stimulating therapies (DOSE) registry Journal of Clinical Oncology 26(15_Suppl): 20637-20637
Fort, J.; Cuevas, X.; García, F.; Pérez-García, R.; Lladós, F.; Lozano, J.; Martín-Malo, A.; Abrigar, P.; Aguilera, J.; Aladrén, M.J.; Alcalá, M.; Alegre, R.; Aliaga, M.A.; Almirall, J.; Alonso, R.; Alvarez, R.; Amador, R.; Amoedo, M.L.; Andrés, B.; Angelet, P.; Antolín, A.; Arambarri, M.; Arenas, M.D.; Argoitia, A.; Arranz, M.; Arraque, A.; Arribas, G.; Arrieta, J.; Arroyo, M.J.; Arteaga, J.; Aurrekoetxea, B.; Avilés, B.; Aznar, Y.; Barbosa, F.; Barril, G.; Basterrechea, M.A.; Belart, M.; Beltran, S.; Bernal, G.; Bernat, A.; Besada, M.E.; Betriu, A.; Biechy, M.M.; Blanco, A.; Blasco, A.; Bolaños, L.; Bonilla, B.; Bordils, A.; Botella, A.; Bravo, J.J.; Calderón, M.T.; Calls, J.; Calpe, J.; Calvar, C.; Calviño, J.A.; Calvo, E.;, 2010: Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 25(8): 2702-2710
Wickramasinghe, S.N.; Hughes, M.; Wasi, P.; Fucharoen, S. 1981: Morphology and kinetics of erythropoiesis in haemoglobin H disease British Journal of Haematology 49(2): 185-188
Moradi, Z.; Maali, A.; Shad, J.Sadeghi.; Farasat, A.; Kouchaki, R.; Moghadami, M.; Ahmadi, M.Hosein.; Azad, M. 2020: Updates on Novel Erythropoiesis-Stimulating Agents: Clinical and Molecular Approach Indian Journal of Hematology and Blood Transfusion: An Official Journal of Indian Society of Hematology and Blood Transfusion 36(1): 26-36
Thavarajah, S.; Choi, M.J. 2019: The use of Erythropoiesis-Stimulating Agents in Patients with CKD and Cancer: a Clinical Approach American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation 74(5): 667-674